Glenmark appoints Dr Penelope Ward as president for clinical R&D
Moneylife Digital Team 03 June 2010

Glenmark Pharmaceuticals Ltd, said it appointed Dr Penelope (Penny) Ward as its new president for clinical research and development (R&D) and chief medical officer.

Dr Ward will be based at Glenmark’s Clinical R&D centre at Oxford in UK. She will oversee the entire clinical development activity for both new chemical entities (NCEs) and new biological entities (NBEs), the company said in a regulatory filing.
Currently, Glenmark has eight programs in clinical development of which six are NCEs and two are NBEs. In her role as chief medical officer, Dr Ward will also guide all medical activities across Glenmark's branded generic markets.

On Thursday, Glenmark ended 0.5% down at Rs264 on the Bombay Stock Exchange, while the benchmark Sensex closed 1.7% up at 17,022 points.

Comments
Array
Free Helpline
Legal Credit
Feedback